| Title |
RETRACTED ARTICLE: Bio-HMGB1 from breast cancer contributes to M-MDSC differentiation from bone marrow progenitor cells and facilitates conversion of monocytes into MDSC-like cells
|
|---|---|
| Published in |
Cancer Immunology, Immunotherapy, December 2016
|
| DOI | 10.1007/s00262-016-1942-2 |
| Pubmed ID | |
| Authors |
Zhaoliang Su, Ping Ni, Peng She, Yueqin Liu, Seidu A. Richard, Wenlin Xu, Haitao Zhu, Jia Wang |
| Abstract |
Myeloid-derived suppressor cells (MDSC) constitute the major cell population that regulates immune responses. They are known to accumulate in tumors, chronic inflammatory and autoimmune diseases. Previous data indicate that high mobility group box 1(HMGB1) facilitates MDSC differentiation from bone marrow, suppresses NK cells, CD4(+) and CD8(+) T cells and is involved in cancer development. However, it remains unclear what potential mechanisms of HMGB1 facilitate MDSC differentiation. In the present work, we clearly demonstrate that HMGB1 secreted by cancer cells is N-glycosylated at Asn37, which facilitates monocytic (M)-MDSC differentiation from bone marrow via the p38/NFκB/Erk1/2 pathway and also contributes to conversion of monocytes into MDSC-like cells; HMGB1 blockade by a monoclonal antibody against the HMGB1 B box obviously reduced the accumulation of M-MDSC in tumor-bearing mice, delaying tumor growth and development; additionally, MDSC expansion and HMGB1 up-regulation were also found in breast cancer patients. All these data indicate that HMGB1 might be a potential tumor immunotherapy target. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Mexico | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 29 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 1 | 3% |
| Unknown | 28 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 7 | 24% |
| Student > Bachelor | 3 | 10% |
| Other | 3 | 10% |
| Professor | 2 | 7% |
| Student > Ph. D. Student | 2 | 7% |
| Other | 4 | 14% |
| Unknown | 8 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 28% |
| Agricultural and Biological Sciences | 4 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 7% |
| Biochemistry, Genetics and Molecular Biology | 2 | 7% |
| Immunology and Microbiology | 2 | 7% |
| Other | 2 | 7% |
| Unknown | 9 | 31% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 February 2017.
All research outputs
#15,448,169
of 22,957,478 outputs
Outputs from Cancer Immunology, Immunotherapy
#2,164
of 2,890 outputs
Outputs of similar age
#256,433
of 421,511 outputs
Outputs of similar age from Cancer Immunology, Immunotherapy
#16
of 28 outputs
Altmetric has tracked 22,957,478 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,890 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.2. This one is in the 18th percentile – i.e., 18% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 421,511 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 30th percentile – i.e., 30% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one is in the 10th percentile – i.e., 10% of its contemporaries scored the same or lower than it.